82_FR_28989 82 FR 28868 - National Institute on Drug Abuse; Notice of Closed Meeting

82 FR 28868 - National Institute on Drug Abuse; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 121 (June 26, 2017)

Page Range28868-28869
FR Document2017-13219

Federal Register, Volume 82 Issue 121 (Monday, June 26, 2017) 
[Federal Register Volume 82, Number 121 (Monday, June 26, 2017)]
[Notices]
[Pages 28868-28869]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-13219]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the

[[Page 28869]]

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel NIDA Blending Initiative (2248).
    Date: June 27, 2017.
    Time: 11:00 a.m. to 12:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Lyle Furr, Scientific Review Officer, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
9550, (301) 827-5702, lf33c.nih.gov.

(Catalogue of Federal Domestic Assistance Program No.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: June 20, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-13219 Filed 6-23-17; 8:45 am]
 BILLING CODE 4140-01-P

28868 Federal Register / Vol. 82, No. 121 / Monday, June 26, 2017 / Notices DEPARTMENT OF HEALTH AND DEPARTMENT OF HEALTH AND 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., HUMAN SERVICES HUMAN SERVICES as amended. The grant applications and the discussions could disclose National Institutes of Health National Institutes of Health confidential trade secrets or commercial property such as patentable material, National Eye Institute; Notice of Closed National Heart, Lung, and Blood and personal information concerning Meetings Institute; Notice of Closed Meeting individuals associated with the grant Pursuant to section 10(d) of the applications, the disclosure of which Pursuant to section 10(d) of the Federal Advisory Committee Act, as would constitute a clearly unwarranted Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is invasion of personal privacy. amended (5 U.S.C. App.), notice is hereby given of the following meeting. Name of Committee: Center for Scientific hereby given of the following meetings. The meeting will be closed to the Review Special Emphasis Panel; PAR 16– The meetings will be closed to the public in accordance with the 121: Early-Stage Preclinical Validation of public in accordance with the provisions set forth in section Therapeutic Leads for Diseases of Interest to 552b(c)(6), Title 5 U.S.C., as amended. the NIDDK. provisions set forth in sections Date: July 18, 2017. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., The grant applications and the Time: 12:00 p.m. to 5:00 p.m. as amended. The grant applications and discussions could disclose confidential Agenda: To review and evaluate grant the discussions could disclose trade secrets or commercial property applications. confidential trade secrets or commercial such as patentable material, and Place: National Institutes of Health, 6701 personal information concerning Rockledge Drive, Bethesda, MD 20892 property such as patentable material, individuals associated with the grant (Virtual Meeting). and personal information concerning applications, the disclosure of which Contact Person: Antonello Pileggi, MD, individuals associated with the grant would constitute a clearly unwarranted Ph.D., Scientific Review Officer, Center for applications, the disclosure of which invasion of personal privacy. Scientific Review, National Institutes of would constitute a clearly unwarranted Health, 6701 Rockledge Drive, Room 6166, Name of Committee: National Heart, Lung, Bethesda, MD 20892–7892, (301) 402–6297, invasion of personal privacy. and Blood Institute Special Emphasis Panel; pileggia@csr.nih.gov. Name of Committee: National Eye Institute International Strategic Timing of Antiretroviral Therapy Trial. Name of Committee: Center for Scientific Special Emphasis Panel; NEI Translational Review Special Emphasis Panel; Member Research Program to Develop Novel Date: July 18, 2017. Time: 12:00 p.m. to 2:00 p.m. Conflict: Eukaryotic Parasites and Vectors. Therapies and Devices for the Treatment of Date: July 24–25, 2017. Agenda: To review and evaluate grant Visual System Disorders (R24). Time: 8:00 a.m. to 6:00 p.m. applications. Date: July 25, 2017. Place: National Institutes of Health, 6701 Agenda: To review and evaluate grant Time: 8:00 a.m. to 4:30 p.m. Rockledge Drive, Room 7188, Bethesda, MD applications. Agenda: To review and evaluate grant 20892 (Telephone Conference Call). Place: National Institutes of Health, 6701 applications. Contact Person: Chang Sook Kim, Phd., Rockledge Drive, Bethesda, MD 20892 Place: Hilton Garden Inn Bethesda, 7301 Scientific Review Officer, Office of Scientific (Virtual Meeting). Waverly Street, Bethesda, MD 20814. Review/DERA, National Heart, Lung, and Contact Person: Fouad A. El-Zaatari, Ph.D., Blood Institute, 6701 Rockledge Drive, Room Scientific Review Officer, Center for Contact Person: Brian Hoshaw, PhD., 7188, Bethesda, MD 20892–7924, 301–827– Scientific Review, National Institutes of Scientific Review Officer, National Eye 7940, carolko@mail.nih.gov. Health, 6701 Rockledge Drive, Room 3186, Institute, National Institutes of Health, MSC 7808, Bethesda, MD 20892, (301) 435– Division of Extramural Research, 5635 (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for 1149, elzaataf@csr.nih.gov. Fishers Lane, Suite 1300, Rockville, MD (Catalogue of Federal Domestic Assistance Sleep Disorders Research; 93.837, Heart and 20892, 301–451–2020, hoshawb@ Vascular Diseases Research; 93.838, Lung Program Nos. 93.306, Comparative Medicine; mail.nih.gov. Diseases Research; 93.839, Blood Diseases 93.333, Clinical Research, 93.306, 93.333, Name of Committee: National Eye Institute, and Resources Research, National Institutes 93.337, 93.393–93.396, 93.837–93.844, Special Emphasis Panel; NEI Secondary Data of Health, HHS) 93.846–93.878, 93.892, 93.893, National Analysis Grant Applications. Dated: June 20, 2017. Institutes of Health, HHS) Date: July 26, 2017. Michelle Trout, Dated: June 20, 2017. Time: 9:00 a.m. to 12:00 p.m. Program Analyst, Office of Federal Advisory Sylvia L. Neal, Agenda: To review and evaluate grant Committee Policy. Program Analyst, Office of Federal Advisory applications. [FR Doc. 2017–13218 Filed 6–23–17; 8:45 am] Committee Policy. Place: National Institutes of Health 5635 [FR Doc. 2017–13212 Filed 6–23–17; 8:45 am] BILLING CODE 4140–01–P Fishers Lane, Bethesda, MD 20892 (Virtual BILLING CODE 4140–01–P Meeting). Contact Person: Jeanette M. Hosseini, PhD., DEPARTMENT OF HEALTH AND Scientific Review Officer 5635 Fishers Lane, HUMAN SERVICES DEPARTMENT OF HEALTH AND Suite 1300, Bethesda, MD 20892, 301–451– HUMAN SERVICES 2020, jeanetteh@mail.nih.gov. National Institutes of Health (Catalogue of Federal Domestic Assistance National Institutes of Health Program Nos. 93.867, Vision Research, Center for Scientific Review; Notice of National Institutes of Health, HHS) Closed Meetings National Institute on Drug Abuse; sradovich on DSK3GMQ082PROD with NOTICES Notice of Closed Meeting Dated: June 20, 2017. Pursuant to section 10(d) of the Natasha M. Copeland, Federal Advisory Committee Act, as Pursuant to section 10(d) of the Program Analyst, Office of Federal Advisory amended (5 U.S.C. App.), notice is Federal Advisory Committee Act, as Committee Policy. hereby given of the following meetings. amended (5 U.S.C. App), notice is The meetings will be closed to the hereby given of the following meeting. [FR Doc. 2017–13216 Filed 6–23–17; 8:45 am] public in accordance with the The meeting will be closed to the BILLING CODE 4140–01–P provisions set forth in sections public in accordance with the VerDate Sep<11>2014 17:04 Jun 23, 2017 Jkt 241001 PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 E:\FR\FM\26JNN1.SGM 26JNN1

Federal Register / Vol. 82, No. 121 / Monday, June 26, 2017 / Notices 28869 provisions set forth in sections Place: National Human Genome Research and Research Training, National Institutes of 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Institute, National Institutes of Health, 5635 Health, HHS) as amended. The contract proposals and Fishers Lane, Suite 3046, Bethesda, MD Dated: June 20, 2017. 20892 (Telephone Conference Call). the discussions could disclose David Clary, Contact Person: Barbara J. Thomas, Ph.D., confidential trade secrets or commercial Scientific Review Officer, Scientific Review Program Analyst, Office of Federal Advisory property such as patentable material, Branch, National Human Genome Research Committee Policy. and personal information concerning Institute, National Institutes of Health, 5635 [FR Doc. 2017–13214 Filed 6–23–17; 8:45 am] individuals associated with the contract Fishers Lane, Ste. 4076, MSC 9306, Bethesda, BILLING CODE 4140–01–P proposals, the disclosure of which MD 20892–9306, 301–402–0838, would constitute a clearly unwarranted barbara.thomas@nih.gov. invasion of personal privacy. (Catalogue of Federal Domestic Assistance DEPARTMENT OF HEALTH AND Program Nos. 93.172, Human Genome HUMAN SERVICES Name of Committee: National Institute on Research, National Institutes of Health, HHS) Drug Abuse Special Emphasis Panel NIDA Blending Initiative (2248). Dated: June 20, 2017. Substance Abuse and Mental Health Date: June 27, 2017. Sylvia L. Neal, Services Administration Time: 11:00 a.m. to 12:00 p.m. Program Analyst, Office of Federal Advisory Agenda: To review and evaluate contract Committee Policy. Center for Substance Abuse proposals. Treatment; Notice of Meeting Place: National Institutes of Health, [FR Doc. 2017–13217 Filed 6–23–17; 8:45 am] Neuroscience Center, 6001 Executive BILLING CODE 4140–01–P Pursuant to Public Law 92–463, Boulevard, Rockville, MD 20852 (Telephone notice is hereby given that the Conference Call). Substance Abuse and Mental Health Contact Person: Lyle Furr, Scientific DEPARTMENT OF HEALTH AND Services Administration’s (SAMHSA’s) Review Officer, Office of Extramural Affairs, HUMAN SERVICES Center for Substance Abuse Treatment National Institute on Drug Abuse, NIH, (CSAT) National Advisory Council will DHHS, Room 4227, MSC 9550, 6001 National Institutes of Health Executive Boulevard, Bethesda, MD 20892– meet on August 11, 2017, 11:00 a.m.– 9550, (301) 827–5702, lf33c.nih.gov. 12:00 p.m. (EDT) in a closed National Center for Advancing teleconference meeting. (Catalogue of Federal Domestic Assistance Translational Sciences; Notice of Program No.: 93.279, Drug Abuse and The meeting will include discussions Closed Meeting and evaluations of grant applications Addiction Research Programs, National Institutes of Health, HHS) Pursuant to section 10(d) of the reviewed by SAMHSA’s Initial Review Dated: June 20, 2017. Federal Advisory Committee Act, as Groups, and involve an examination of amended (5 U.S.C. App.), notice is confidential financial and business Natasha M. Copeland, hereby given of the following meeting. information as well as personal Program Analyst, Office of Federal Advisory The meeting will be closed to the information concerning the applicants. Committee Policy. public in accordance with the Therefore, the meeting will be closed to [FR Doc. 2017–13219 Filed 6–23–17; 8:45 am] provisions set forth in sections the public as determined by the BILLING CODE 4140–01–P SAMHSA Acting Deputy Assistant 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and Secretary for Mental Health and the discussions could disclose Substance Use in accordance with Title DEPARTMENT OF HEALTH AND 5 U.S.C. 552b(c)(4) and (6) and Title 5 HUMAN SERVICES confidential trade secrets or commercial property such as patentable material, U.S.C. App. 2, 10(d). National Institutes of Health and personal information concerning Meeting information and a roster of individuals associated with the contract Council members may be obtained by National Human Genome Research proposals, the disclosure of which accessing the SAMHSA Committee Web Institute; Notice of Closed Meeting would constitute a clearly unwarranted site at http://www.samhsa.gov/about-us/ invasion of personal privacy. advisory-councils/csat-national- Pursuant to section 10(d) of the advisory-council or by contacting the Federal Advisory Committee Act, as Name of Committee: National Center for CSAT National Advisory Council amended (5 U.S.C. App.), notice is Advancing Translational Sciences Special Emphasis Panel Platform Delivery—N.A. Designated Federal Officer; Tracy Goss hereby given of the following meeting. (see contact information below). Date: July 19, 2017. The meeting will be closed to the Council Name: SAMHSA’s Center for Time: 8:00 a.m. to 5:30 p.m. public in accordance with the Agenda: To review and evaluate contract Substance Abuse Treatment, National provisions set forth in sections proposals. Advisory Council. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Place: National Institutes of Health, One Date/Time/Type: August 11, 2017, as amended. The grant applications and Democracy Plaza, Room 1066, 6701 11:00 a.m.–12:00 p.m. EDT, Closed. the discussions could disclose Democracy Boulevard, Bethesda, MD 20892 Place: SAMHSA, 5600 Fishers Lane, confidential trade secrets or commercial (Virtual Meeting). Rockville, Maryland 20857. property such as patentable material, Contact Person: Barbara J. Nelson, Ph.D., Contact: Tracy Goss, Designated and personal information concerning Scientific Review Officer Office of Scientific Federal Officer, CSAT National Review, National Center for Advancing individuals associated with the grant Translational Sciences (NCATS), National Advisory Council, 5600 Fishers Lane, applications, the disclosure of which Institutes of Health, 6701 Democracy Blvd., Rockville, Maryland 20857 (mail), sradovich on DSK3GMQ082PROD with NOTICES would constitute a clearly unwarranted Democracy 1, Room 1080, Bethesda, MD Telephone: (240) 276–0759, Fax: (240) invasion of personal privacy. 20892–4874, 301–435–0806, nelsonbj@ 276–2252, Email: tracy.goss@ Name of Committee: Center for Inherited mail.nih.gov. samhsa.hhs.gov. Disease Research Access Committee. (Catalogue of Federal Domestic Assistance Carlos Castillo, Date: July 21, 2017. Program Nos. 93.859, Pharmacology, Time: 11:30 a.m. to 1:30 p.m. Physiology, and Biological Chemistry Committee Management Officer, SAMHSA. Agenda: To review and evaluate grant Research; 93.350, B—Cooperative [FR Doc. 2017–13221 Filed 6–23–17; 8:45 am] applications. Agreements; 93.859, Biomedical Research BILLING CODE 4162–20–P VerDate Sep<11>2014 17:04 Jun 23, 2017 Jkt 241001 PO 00000 Frm 00056 Fmt 4703 Sfmt 9990 E:\FR\FM\26JNN1.SGM 26JNN1


Document Created: 2018-11-14 10:10:40
Document Modified: 2018-11-14 10:10:40
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesJune 27, 2017.
FR Citation82 FR 28868 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR